Acute Myeloid Leukemia in Children

Brenda E. S. Gibson; Martin G. Sauer; Persis Amrolia

doi:10.1007/978-3-030-02278-5_70

Acute Myeloid Leukemia in Children

Review

In: The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 70.

Authors

Brenda E. S. Gibson¹, Martin G. Sauer², Persis Amrolia³

Book Editors

Enric Carreras¹, Carlo Dufour², Mohamad Mohty³, Nicolaus Kröger⁴

Affiliations

¹ Haematology Department, Royal Hospital for Children, University of Glasgow, Glasgow, UK
² Pediatric Hematology, Oncology and Blood Cell Transplantation, Medizinische Hochschule Hannover, Hannover, Germany
³ Department of Bone Marrow Transplant, Great Ormond St Children’s Hospital, London, UK

Book Affiliations

¹ Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Catalunya, Barcelona, Spain
² Hematology Unit, IRCCS Giannina Gaslini, Geneva, Switzerland
³ Department of Hematology, Pierre and Marie Curie University, Paris, France
⁴ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppend, Hamburg, Germany

Excerpt

The outcome for children with acute myeloid leukemia (AML) has serially improved over the past three decades with an overall survival (OS) of 70–75% and event-free survival (EFS) of 60–65% widely reported. Much of this improvement is due to better supportive care, optimization of intensity of treatment including employment of Haematopoietic Stem Cell Transplantation (HSCT) in 1st complete remission (CR1) and better salvage in 2nd complete remission (CR2).

Sections

Publication types

Review